FARMECONOMIA E PERCORSI TERAPEUTICI
International differential pricing: easy in theory but hard in practice
Bruce CM Wang (1), Mohan Purushothaman (1)
How countries pay for patented pharmaceuticals varies widely in terms of complexity of rules and processes. A pharmaceutical pricing scheme should ideally provide affordable drug access to those in need while allowing the manufacturers to receive enough profits to sustain continued technological innovation. Profit-seeking pharmaceutical companies are incentivized to set prices in a way that would maximize their revenues and sustain long term dominance of specific market segments and they understandably attempt to justify these practices as a necessity to cover their R&D investments. Health authorities, on the other hand, typically have a current budget constraint under which they have to work and have some incentive to discount the value of future innovation. While some countries have allowed “free pricing”, others have introduced concepts such as “value-based pricing” or enforced rigid price controls. As one looks across various country markets, there is a range of practices that fall somewhere along this continuum.
(1) Alliance Life Sciences, Jersey City, NJ, USA
Vai all'articolo: http://bit.ly/1gxtDOC